{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-24-000097","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.903488+00:00","generated_at":"2026-05-31T15:09:23.800536+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pacira Q2 2024: Revenue $178M, GAAP EPS $0.39; CMS proposes EXPAREL outpatient reimbursement under NOPAIN","bullets":["Total revenues of $178.0M, up 5% YoY; EXPAREL sales $136.9M (+1.3%), ZILRETTA $30.7M.","GAAP net income $18.9M ($0.39 diluted EPS) vs $25.8M ($0.51) in Q2 2023.","Non-GAAP net income $44.2M ($0.89 diluted EPS) vs $36.0M ($0.71) a year ago; adjusted EBITDA $62.1M.","CMS proposed rule would separately reimburse EXPAREL in HOPD/ASC starting Jan 2025 under NOPAIN Act.","Full-year 2024 revenue guidance reiterated at $680M-$705M; $150M share repurchase program ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-24-000097","json":"https://secwatch.observer/filing/0001396814-24-000097.json","markdown":"https://secwatch.observer/filing/0001396814-24-000097.md","text":"https://secwatch.observer/filing/0001396814-24-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000097/0001396814-24-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000097/pcrx-20240730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:09:23.800536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}